Ku­ra co-founder heads to Asian mul­ti-na­tion­al as biotech eyes the goal posts for lead drug

Six years af­ter Ku­ra On­col­o­gy snagged a far­ne­syl trans­ferase in­hibitor from J&J and leapt straight in­to clin­i­cal de­vel­op­ment, one of the biotech’s founders is leav­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER